Thursday, July 13, 2023 8:09:58 AM
Echo Lake Capital Increase Offer to Acquire Quince Therapeutics
Increases offer to $1.80 per share + CVR to receive 85% of the future net proceeds of Quince as part of the Lighthouse Pharmaceuticals transaction
Recent QNCX News
- Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia • Business Wire • 06/25/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/08/2024 01:08:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/08/2024 01:04:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/08/2024 12:59:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:17:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 06:37:39 PM
- Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System • Business Wire • 06/03/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 11:30:45 AM
- Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results • Business Wire • 05/13/2024 11:00:00 AM
- Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference • Business Wire • 05/06/2024 08:05:00 PM
- Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results • Business Wire • 04/01/2024 11:00:00 AM
- Quince Therapeutics Launches Scientific Advisory Board • Business Wire • 02/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:00:43 PM
- Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors • Business Wire • 02/15/2024 12:00:00 PM
- Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference • Business Wire • 02/07/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 10:53:07 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/05/2024 09:01:33 PM
- Quince Therapeutics to Participate at Investor Events in January 2024 • Business Wire • 01/04/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:02:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:08:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/14/2023 11:21:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:06:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 11:30:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 06:38:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 09:54:48 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM